No harm from angiotensin-converting enzyme inhibitors or angiotensin receptor inhibitors in patients with COVID-19. Results of a prospective study on a hospital-based cohort

  • Gian Paolo Anzola | gpanzola@gmail.com San Camillo Hospital, Brescia, Italy. https://orcid.org/0000-0001-7361-4087
  • Clara Bartolaminelli Azienda Territoriale Sanitaria (Territorial Health Authority), Brescia, Italy.
  • Gina Alessandra Gregorini University of Brescia, Italy.
  • Chiara Coazzoli Azienda Territoriale Sanitaria (Territorial Health Authority), Brescia, Italy.
  • Francesca Gatti Emergency Department, Gavardo Hospital, Brescia, Italy.
  • Alessandra Mora Emergency Department, Gavardo Hospital, Brescia, Italy.
  • Dimitrios Charalampakis Emergency Department, Gavardo Hospital, Brescia, Italy.
  • Andrea Palmigiano Emergency Department, Gavardo Hospital, Brescia, Italy.
  • Michele De Simone Emergency Department, Gavardo Hospital, Brescia, Italy.
  • Alice Comini Emergency Department, Gavardo Hospital, Brescia, Italy.
  • Erica Dellaglio Emergency Department, Gavardo Hospital, Brescia, Italy.
  • Salvatore Cassetti Emergency Department, Gavardo Hospital, Brescia, Italy.
  • Maurizio Chiesa Emergency Department, Gavardo Hospital, Brescia, Italy.
  • Francesca Spedini Emergency Department, Gavardo Hospital, Brescia, Italy.
  • Patrizia d'Ottavi Azienda Territoriale Sanitaria (Territorial Health Authority), Brescia, Italy.
  • Maria Cristina Savio Emergency Department, Gavardo Hospital, Brescia, Italy.

Abstract

This study aims to assess the effect of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor inhibitors (ARBs) on the course of COVID-19. It is a prospective study on 221 (M/F ratio= 143/78, mean age 72±13) consecutive hypertensive patients with COVID-19: 76 (34.4%) treated with ACEIs, 63 (28.5%) with ARBs and 82 (37.1%) with antihypertensives OTHER than ACEIs or ARBs. They were all followed up until discharge or death. BAD outcome was defined as the need for invasive mechanical ventilation or death. The three classes of medication were well balanced for confounding variables. BAD outcome was overall recorded in 63/221 (28%) patients, in 20/76 (26%) of ACEI, in 17/63 (27%) of ARB and in 26/82 (32%) of OTHER users, with no statistically significant difference in any comparison. These findings refute the hypothesis that treatment with ACEIs or ARBs may negatively affect the course of COVID-19.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Published
2020-09-18
Info
Issue
Section
Brief Reports
Keywords:
COVID-19, angiotensin-converting enzyme inhibitors, angiotensin receptor inhibitors.
Statistics
  • Abstract views: 57

  • PDF: 52
  • HTML: 0
How to Cite
Anzola, G. P., Bartolaminelli, C., Gregorini, G. A., Coazzoli, C., Gatti, F., Mora, A., Charalampakis, D., Palmigiano, A., De Simone, M., Comini, A., Dellaglio, E., Cassetti, S., Chiesa, M., Spedini, F., d’Ottavi, P., & Savio, M. C. (2020). No harm from angiotensin-converting enzyme inhibitors or angiotensin receptor inhibitors in patients with COVID-19. Results of a prospective study on a hospital-based cohort. Italian Journal of Medicine, 14(3), 162-166. https://doi.org/10.4081/itjm.2020.1313